؉ healthy virus carriers often recognize peptide EENLLDVFRM from EBV nuclear antigen 6. However, the strength of this response directly correlates with the HLA B44 subtype expressed by the individual donor. ؉ or B*4403 ؉ target cells irrespective of the HLA B44 subtype expressed by the donors from whom these effectors were isolated. This effect is evident whether the CTL epitope is endogenously processed or exogenously presented. In addition, a comparison of the intracellular transport kinetics of different B44 subtypes revealed that the B*4405 allele is rapidly assembled and arrives in the trans-Golgi compartment at a faster rate than B*4402 or B*4403. Based on these results, we propose that HLA class I alleles that are capable of binding peptides more efficiently from the intracellular pool, and are rapidly assembled and transported, may confer a protective advantage against viral infection.
CD8
ϩ cytotoxic T lymphocytes (CTLs) recognize peptide epitopes, mainly derived from cytoplasmic and nuclear proteins in association with major histocompatibility complex (MHC) class I molecules on the surface of appropriate antigen-presenting cells (32) . Although synthetic peptides can directly prime target cells for lysis by CTLs, recognition of a native antigen requires intracellular processing, which involves cleavage of the antigen into short peptides and their transport into the endoplasmic reticulum (ER), where they associate with MHC class I (1) . The binding of these peptides to newly synthesized MHC class I molecules is important for normal assembly and stability of the MHC and for efficient CTL recognition. The number of peptides within an antigenic protein that can bind to a particular class I molecule is usually considerably larger than the number of epitopes recognized in a CTL response to that antigen, suggesting the existence of a hierarchy with which peptides are presented for immune recognition (8, 26, 28) . As a consequence, the CTL response is frequently dominated by a limited number of epitopes. The class I binding affinities described so far for immunodominant epitopes are generally very high (10, 16, 30) . While it is clear that many immunodominant epitopes exhibit a strong binding affinity, the converse does not always apply; i.e., not all strongly binding peptides are immunodominant epitopes (34) .
A number of possible mechanisms have been proposed to explain this selective immunodominance: the influence of proteasome-mediated proteolysis of the native antigen (17, 25) , peptide affinity for MHC molecules (5, 33) , MHC-peptide complex stability (11) , and the T-cell repertoire (6) . Furthermore, the availability of peptides for the assembly of MHCpeptide complexes in the ER, which has previously been shown to be restricted by the activity of the transporters associated with antigen processing, is also an important factor influencing the level of peptide presentation (22, 24, 29) . It is not clear, however, to what extent intracellular folding and transport of MHC molecules influence T-cell repertoire selection and immunodominance in a class I-restricted CTL response.
In this study, we have investigated the issue of CTL immunodominance in the context of Epstein-Barr virus (EBV) in which CTLs play a pivotal role in restricting the proliferation of EBV-infected B cells (13) . Earlier studies of healthy virus carriers have shown that this CTL response is mainly directed to EBV nuclear antigens (EBNA2 to EBNA6) and latent membrane proteins (12, 20) . Multiple peptide epitopes, restricted through different MHC class I antigens, have been identified within these latent antigens (13) . We have previously proposed that the level and specificity of CTL responses in healthy virus carriers is strongly influenced by the host MHC genotype (13 
MATERIALS AND METHODS
Establishment and maintenance of cell lines. EBV-transformed lymphoblastoid cell lines (LCLs) from seropositive donors DM (HLA A24, A29, B47, B*4405), IT (HLA A1, A3 B7 B*4402), CM (HLA A11, A24, B7, B*4405), PM (HLA A11, A29, B7 B*4403), CS (HLA A3, A23, B35, B*4403), SE (HLA A2, A29, B60, B*4403), BK (HLA A1, A2, B8, B*4403), DY (HLA A11, A32, B35, B*4402), CF (HLA A1, A2, B8, B*4402), and KE (HLA A32, A26, B49, B*4402) were established by exogenous virus transformation of peripheral B cells, using EBV derived from the B95.8 cell line (19) . All LCLs were routinely maintained in RPMI 1640 containing 2 mM glutamine, 100 IU of penicillin per ml, 100 g of streptomycin per ml, and 10 to 20% fetal calf serum (FCS) (growth medium).
To generate phytohemagglutinin (PHA) blasts, unfractionated mononuclear (UM) cells were stimulated with PHA (Commonwealth Serum Laboratories, Melbourne, Australia), and after 3 days, growth medium containing MLA-144 supernatant and recombinant interleukin-2 (rIL-2) was added (referred to as T-cell growth medium) (4) . PHA blasts were propagated with biweekly replacement of rIL-2 and MLA-144 supernatant (no further PHA added) for up to 6 weeks.
Source (2, 19) . Briefly, 2 ϫ 10 6 peripheral blood lymphocytes from these donors were stimulated in 2 ml of growth medium with autologous ␥-irradiated (8,000 rads) B95.8-transformed LCLs (responder/stimulator ratio of 50:1). After 3 days, cells were dispersed and seeded in 0.35% agarose (SeaPlaque; FMC Corp., Rockland, Maine) containing T-cell growth medium. Colonies were harvested after a further 3 to 4 days and amplified in culture with biweekly restimulation with ␥-irradiated (8,000 rads) autologous LCLs in T-cell growth medium. The EBV and antigen specificity of each CTL clone was confirmed using autologous LCLs and recombinant vaccinia virus constructs encoding individual EBV antigens (12, 14, 15) . The peptide specificity of each CTL clone was also determined by using synthetic peptides (4, 18 ϩ ) were fused with LCLs from donor CM (B*4405 ϩ ), using polyethylene glycol (molecular weight, 2,000). These fused cells were cultured for 72 h at 37°C, and B*4402/B*4405 and B*4403/B*4405 chimeras were separated with a FACS Vantage (Becton Dickinson and Co., Mountain View, Calif.), using HLA-specific monoclonal antibodies. It is important to mention here that donors CF and BK are positive for HLA B8, while donor CM is positive for HLA B7. For fluorescence-activated cell sorting, cells were initially incubated with fluorescein isothiocyanate-labeled HLA B7-specific monoclonal antibody (Behring Diagnostics, Berlin, Germany) followed by biotin-labeled HLA B8-specific monoclonal antibody (One lambda Inc., La Jolla, Calif.). Following extensive washing with phosphate-buffered saline-1% FCS, cells were incubated with streptavidin-labeled red670 (Gibco BRL, Bethesda, Md.). Cells expressing both HLA B7 and HLA B8 were sorted twice and checked by fluorescence-activated cell sorting analysis for double-positive cells; 95 to 97% of the sorted cells were positive for both HLA markers. These chimeric cell lines were used as targets in a standard 51 Cr release assay. Recombinant vaccinia virus. A recombinant vaccinia virus construct encoding EBNA6 (Vacc.EBNA6) and a vaccinia virus construct made by insertion of the pSC11 vector alone and negative for thymidine kinase (Vacc.TK Ϫ ) have been previously described (12, 15) .
Cytotoxicity assay. CTL clones were screened in the standard 5-h chromium release assay (19) . Briefly, 51 Cr-labeled LCLs or PHA blasts from B*4402, B*4403, and B*4405 ϩ individuals were incubated for 1 h without or with various concentrations of peptide epitope EENLLDVFRM. Following incubation, excess peptide was washed off with serum-free medium. Peptide EENLLDVFRM was synthesized by a simultaneous multiple peptide synthesis technique as described by Burrows et al. (4) . CTL clones specific for peptide EENLLDVFRM were used as effectors in these assays. In some experiments, LCLs were infected with vaccinia virus constructs encoding EBNA6 at a multiplicity of infection of 10:1 for 12 to 14 h and used as targets in a standard chromium release assay.
LDA. UM cells from HLA B*4402 ϩ , B*4403 ϩ , and B*4405 ϩ donors were distributed in graded numbers (twofold dilution) from 3.75 ϫ 10 2 to 5 ϫ 10 4 cells per well in round-bottom microtiter plates. Approximately 5 ϫ 10 4 ␥-irradiated (8,000 rads) autologous LCLs were added to give a total volume of 100 l. Twenty-four replicates were used at each concentration in each experiment, and an equal number of control wells were set up in which no stimulator cells were added. Cultures were fed on days 4 and 7 with 50 l of medium supplemented with 20 U of rIL-2 and 30% (vol/vol) supernatant from MLA-144 cultures. On day 10, each CTL microculture was split into two replicates, and the cells were used as effectors in a standard 5-h 51 Cr release assay against autologous PHA blasts precoated with peptide EENLLDVFRM or left uncoated. Wells were scored as positive when the percent specific chromium release exceeded the mean release from control wells by 3 standard deviations. Limiting dilution analysis (LDA) was performed by the method of maximum likelihood estimation (7) . Data from all experiments were compatible with the hypothesis of single-hit kinetics (P Ͼ 0.4), and precursor estimates are given with 95% confidence limits.
1D-IEF. To analyze intracellular transport of HLA B44 subtypes, 3 ϫ 10 35 S]methioninecysteine for 10 min at 37°C. Cells were chased for 0, 5, 10, 30, 60, and 120 min in RPMI 1640 supplemented with 1 mM methionine-cysteine and 10% FCS and lysed in 1% digitonin-containing lysis mixture for 2 h on ice. After overnight preclearing with normal rabbit serum, the lysates were immunoprecipitated with W6/32 and the complexes were recovered with protein A-Sepharose. All samples were analyzed by one-dimensional isoelectric focusing (1D-IEF) (21) . ) . Similarly, no EENLLDVFRM-specific CTLp were detected from donors SE and PM (data not shown). To exclude the possibility that competition among T-cell clones stimulated with LCLs, which recognize other EBV epitopes, was involved in restricting the CTL response to EENLLDVFRM in vitro, CTLp frequencies from donors CM, CS, and CF were also estimated in cultures stimulated with autologous UM cells precoated with synthetic peptide EENLLDVFRM. In accordance with the results shown in Fig. 1 , the precursor frequency estimates were comparable to those detected following stimulation with autologous LCLs (data not shown).
RESULTS

Individuals
To further confirm the data obtained from LDA, EBVspecific CTL clones were established by using an agar cloning technique from HLA B*4405 ϩ (DM), B*4403 ϩ (CS and SE) and B*4402 ϩ (IT, KE, and DY) donors by stimulating UM cells with the autologous LCLs. As shown in Table 1 , more than 80% of the EBV-specific clones from donor DM recognized EENLLDVFRM peptide. On the other hand, only 0 to 10% of the virus-specific CTL clones from donors CS, SE, IT, KE, and DY recognized this EBV epitope. A similar frequency of CTL clones specific for the EENLLDVFRM peptide was consistently seen in multiple blood samples from these donors over a period of 5 years.
HLA B*4405 is more efficient in endogenous and exogenous presentation of the EENLLDVFRM epitope than HLA B*4402 and B*4403. To determine whether the disparity in CTLp frequency could be due to a difference in the presentation of the EENLLDVFRM epitope by different subtypes of HLA B44, we first compared the lysis of HLA B44
ϩ LCLs by CTL ϩ LCLs (Fig. 2b ). This disparity in the level of lysis was not due to a difference in the expression of EBNA6 gene in these cells, since comparable levels of EBNA6 were detected when analyzed by immunoblotting (data not shown). Moreover, a similar contrast differential in CTL recognition was also seen with another CTL clone (CM13) from a B*4405 ϩ donor CM (Fig. 2c) . Interestingly, although overexpression of EBNA6 in B*4402 ϩ and B*4403 ϩ LCLs, following infection with a recombinant vaccinia virus encoding this antigen (Vacc.EBNA6), increased the level of CTL recognition by the CM13 clone, the differential pattern of lysis was maintained (Fig. 2c) .
In the next set of experiments, we examined the exogenous presentation efficiency of peptide EENLLDVFRM by the different subtypes of HLA B44. PHA blasts from donors DM (B*4405), CS (B*4403), and CF (B*4402) were presensitized with various concentrations of peptide EENLLDVFRM and then exposed to specific CTL clones or polyclonal CTLs. As illustrated in Fig. 3a ϩ targets was approximately 0.003 g/ml, while for B*4402 and B*4403 this concentration was 100-fold higher (0.1 to 0.3 g/ml). To confirm that this difference in half-maximal lysis was not restricted to these specific CTL clones, we repeated this analysis using an EENLLDVFRM-specific polyclonal CTL line from donor DM. As shown in Fig. 3d, (Fig. 4) . a Each of the experiment data presented above refers to a separate blood sample collected from these donors between 1990 and 1995.
b EBV-specific CTL clones from HLA B44 ϩ donors were isolated as described in Materials and Methods. The EBV specificity of these CTL clones was confirmed as described previously (12) .
c Percentage of EBV-specific CTL clones specific for the EENLLDVFRM epitope. EENLLDVFRM specificity of the clone was confirmed as described elsewhere (4, 18 ϩ donors were exposed to EENLLDVFRM-specific CTL clones (DM D10, CS27, and CM13) at different E/T ratios (a and b) or at a fixed E/T ratio of 4:1 (c). In some experiments, B44
ϩ LCLs were infected with recombinant vaccinia virus encoding EBNA6 antigen (which includes EENLLDVFRM epitope) and then used as targets in a standard 51 Cr release assay (c).
HLA B44 subtypes display significant variation in intracellular maturation and transport kinetics. Earlier studies have revealed that peptide loading of MHC molecules contributes directly to their intracellular transport and that many of the HLA class I alleles differ in efficiency of assembly (23, 27, 31) . To explore the possibility that variation in CTL recognition of peptide bound to the various HLA B44 subtypes was also affected by the difference in the rate of maturation and intracellular transport of these subtypes, HLA B44 ϩ LCLs were studied by pulse-chase labeling and analyzed on 1D-IEF gels as described in Materials and Methods. Marked differences in the kinetics of assembly were noted between the different HLA class I alleles. Three representative gels showing pulse-chase analysis in HLA B*4405 ϩ , B*4402 ϩ , and B*4403 ϩ cell lines are illustrated in Fig. 5 . One way of visualizing intracellular transport of newly assembled MHC class I molecules is by following the time-dependent disappearance of the nonsialylated form of class I heavy chains (indicating transport out of the ER lumen), which correlates with the appearance of the sialylated form upon arrival in the trans-Golgi. In Fig. 5 , it is clearly evident that the sialylated forms (labeled S) of the B*4405 allele can be seen at the 0-min chase, whereas the sialylated forms of B*4402 and B*4403 do not appear until after 5-and 30-min chases, respectively. Moreover, an analysis of unsialylated forms (labeled O) of the B44 alleles indicates a significant reduction in the 35 S-labeled B*4405 allele after 10 min of chase, while the unsialylated B*4403 and B*4402 alleles disappear after 30 min of chase. Thus, the B*4405 allele is assembled and transported more efficiently than the B*4402 and B*4403 alleles.
DISCUSSION
Hierarchies among MHC class I-restricted CTL responses to intracellular pathogens have attracted considerable attention, since CTL epitopes which elicit strong responses might be preferential targets for immunotherapy and vaccine design. Very limited information is available on the factors responsible for these hierarchies in the CTL response. In the present study, we have investigated this issue in the context of a herpesvirus, EBV, that is known to establish a persistent infection in healthy individuals and is associated with a number of human malignancies. It is now well established that EBV-specific memory T cells are responsible for controlling the level of EBV-positive B lymphocytes and that the majority of these T (4, 13, 19) . The CTL response to the HLA B44-restricted epitope EENLLDVFRM from EBNA6 in healthy individuals is a classic example of this phenomenon (3, 12) . We have shown that healthy seropositive individuals carrying different subtypes of the HLA B44 antigen exhibit a discrete hierarchy in their CTL responses to the EENLLDVFRM epitope. This phenomenon appears to be strongly influenced by the peptide-MHC affinity and/or intracellular maturation and transport kinetics of MHC molecules. The possibility that the host MHC genotype can influence the strength of the CTL response to an individual CTL epitope has previously been proposed based on preliminary experiments with polyclonal CTL cultures from HLA B44 ϩ EBVimmune donors. In the present study, we have substantiated this assumption by demonstrating that CTLp specific for EENLLDVFRM are seen more frequently in B*4405 ϩ individuals than in B*4402 ϩ and B*4403 ϩ virus carriers. Furthermore, a similar pattern of response was also seen in the number of EENLLDVFRM-specific CTL clones isolated from B*4402 ϩ , B*4403 ϩ , and B*4405 ϩ donors over a period of 5 years. More than 60 to 80% of the CTL clones isolated from B*4405 ϩ individuals were EENLLDVFRM specific, while 0 to 5% of the CTL clones from B*4402 ϩ and B*4403 ϩ donors were specific for this epitope. To understand the molecular basis of this hierarchy, we analyzed the endogenous and exogenous presentation of EENLLDVFRM by target cells expressing different subtypes of HLA B44. In the first set of experiments, we noted that the specific CTL clones recognized ϩ targets by all CTL clones irrespective of the HLA B44 subtype expressed by the donors from whom these effectors were isolated. Thus, it is unlikely that the difference in T-cell repertoire in these individuals is responsible for a strong or a weak response to EENLLDVFRM. On the other hand, the disparate CTL recognition of the EENLLDVFRM peptide in association with the different subtypes of HLA B44 likely reflects the relative abundance of corresponding class Ipeptide complexes on target cells, and this may be influenced by two distinct factors. First, it is possible that the three subtypes of HLA B44 have different affinities for this peptide. Indeed, the data shown in Fig. 3 strongly argue in favor of this notion. Comparison of the amino acid sequences of the three different subtypes of HLA B44 shows that they differ by a single amino acid at position 116 or 156 (9, 35) . It is possible that the difference between B*4405 and the other subtypes at position 116, which forms part of pocket F of the peptide binding cleft for MHC, influences the binding of EENLLDVFRM. Indeed, the tyrosine residue at position 116 of the B*4405 subtype is likely to interact more favorably with the methionine residue at the carboxy terminus of the peptide, while aspartic acid, a negatively charged residue, at the same position in B*4402 and B*4403 might reduce the efficiency of binding of the EENLLDVFRM peptide.
It is possible that, in addition to differences in peptide binding efficiencies, the differential rates of intracellular assembly and transport of HLA B44 subtypes also contribute to the disparate efficiency in the presentation of the EENLLDVFRM epitope. Although earlier studies have shown that class I molecules display marked differences in the efficiency of assembly and transport (32) , the biological significance of this observation is not understood. Data presented in this study argue in favor of a model in which efficient peptide binding and rapid intracellular assembly and transport kinetics by the MHC alleles contribute to a strong CTL response. It is important to mention here that since a single peptide is unlikely to induce an effect on the overall rate of transport of an individual class I allele, the specific rate in transport of each HLA B44 subtype is probably an intrinsic property of that allele. Thus, both efficient peptide binding and rapid transport kinetics have a synergistic effect on the presentation of the EENLLDVFRM epitope. Preliminary studies carried out in our laboratory have shown a similar strong correlation between other rapid-assembly alleles and immunodominant responses. HLA B8 and HLA B35 alleles, which are rapidly assembled and transported (32) , consistently display strong responses, while weaker responses are seen for slowly assembling alleles such as HLA A3 and HLA B51 (unpublished observations).
Taken together, the data presented in this study strongly suggest that class I alleles that efficiently bind peptides in the ER and are rapidly assembled and transported to the cell surface for presentation to CTL may provide a selective advantage in their ability to present peptide epitopes and confer a protective advantage against EBV infection. More importantly, these observations have significant implications for any future EBV vaccine designed to control acute or persistent viral infection. It is clear from the data presented here that HLA subtype distribution within different individuals might influence the long-term efficacy of CTL epitope-based vaccines. 
